Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 28;14(11):2677.
doi: 10.3390/cancers14112677.

Nanomedicine for the Delivery of RNA in Cancer

Affiliations
Review

Nanomedicine for the Delivery of RNA in Cancer

Michele Ghidini et al. Cancers (Basel). .

Abstract

The complexity, and the diversity of the different types of cancers allied to the tendency to form metastasis make treatment efficiency so tricky and often impossible due to the advanced stage of the disease in the diagnosis. In recent years, due to tremendous scientific breakthroughs, we have witnessed exponential growth in the elucidation of mechanisms that underlie carcinogenesis and metastasis. The development of more selective therapies made it possible to improve cancer treatment. Although interdisciplinary research leads to encouraging results, scientists still have a long exploration journey. RNA technology represents a promise as a therapeutic intervention for targeted gene silencing in cancer, and there are already some RNA-based formulations in clinical trials. However, the use of RNA as a therapeutic tool presents severe limitations, mainly related to its low stability and poor cellular uptake. Thus, the use of nanomedicine employing nanoparticles to encapsulate RNA may represent a suitable platform to address the major challenges hampering its therapeutic application. In this review, we have revisited the potential of RNA and RNA-associated therapies to fight cancer, also providing, as support, a general overview of nanoplatforms for RNA delivery.

Keywords: RNA; cancer; drug delivery systems; nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Main RNA used for cancer therapy.
Figure 2
Figure 2
Schematic representation of nanoparticles used in RNA delivery.
Figure 3
Figure 3
Structures of some common lipids/polymers used for preparing nanoparticles.

References

    1. Bumcrot D., Manoharan M., Koteliansky V., Sah D.W. RNAi therapeutics: A potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2006;2:711–719. doi: 10.1038/nchembio839. - DOI - PMC - PubMed
    1. Liang X., Li D., Leng S., Zhu X. RNA-based pharmacotherapy for tumors: From bench to clinic and back. Biomed. Pharmacother. 2020;125:109997. doi: 10.1016/j.biopha.2020.109997. - DOI - PubMed
    1. Sliva K., Schnierle B.S. Selective gene silencing by viral delivery of short hairpin RNA. Virol. J. 2010;7:248. doi: 10.1186/1743-422X-7-248. - DOI - PMC - PubMed
    1. Pinel K., Diver L.A., White K., McDonald R.A., Baker A.H. Substantial Dysregulation of miRNA Passenger Strands Underlies the Vascular Response to Injury. Cells. 2019;8:83. doi: 10.3390/cells8020083. - DOI - PMC - PubMed
    1. Weng Y., Xiao H., Zhang J., Liang X.J., Huang Y. RNAi therapeutic and its innovative biotechnological evolution. Biotechnol. Adv. 2019;37:801–825. doi: 10.1016/j.biotechadv.2019.04.012. - DOI - PubMed

LinkOut - more resources